Sasaki Tsuneo
Dept of Chemotherapy, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan.
Gan To Kagaku Ryoho. 2004 Nov;31(12):1947-51.
The Japanese Gastric Cancer Association issued a revised edition of gastric cancer treatment guidelines in April 2004. Distinctive features of this revision are adopting newly published literatures after the first edition of the guidelines, laparoscopy-assisted gastrectomy and perioperative management, and illustrating evidence levels in the clinical study of chemotherapy. The treatment protocol of the phase III study is an actual example of this. Gastric cancer treatment in Japan leads the world when considering operation and endoscopic treatment. However, there are only few controlled randomized clinical trials in Japan, and many low quality literatures. On the other hand, an evaluation of the consensus of gastric cancer treatment indicates that it is a high evidence level. Furthermore, a revised edition of chemotherapy was the only one that could be able to show a high evidence level. According to a questionnaire investigation of the revised guidelines, more than 90% of the respondents (the members of Japanese Gastric Cancer Association) have used the guidelines. Hence, the role of the guidelines is important.
日本胃癌协会于2004年4月发布了胃癌治疗指南修订版。本次修订的显著特点是采用了指南第一版之后新发表的文献、腹腔镜辅助胃切除术及围手术期管理,并阐明了化疗临床研究中的证据级别。III期研究的治疗方案就是一个实际例子。在手术和内镜治疗方面,日本的胃癌治疗引领世界。然而,日本仅有少数对照随机临床试验,且存在许多低质量文献。另一方面,对胃癌治疗共识的评估表明其证据级别较高。此外,化疗修订版是唯一能够呈现高证据级别的版本。根据对修订指南的问卷调查,超过90%的受访者(日本胃癌协会成员)使用过该指南。因此,指南的作用很重要。